Skip to main content

Table 5 Association between genotypes of MMP9, 2 and 3 and NSCLC patients' survival of CAPUA study

From: Genetic polymorphisms in MMP 2, 9 and 3genes modify lung cancer risk and survival

Genotypes Patients Deaths MST
(months)
Crude HR 95% CI HRa 95% CI
MMP9 n = 625       
C/C 477 447 10.1 1.00   1.00  
C/T 144 131 9.3 0.91 0.74-1.10 1.03 0.84-1.26
T/T 4 4 12.8 1.17 0.44-3.13 0.85 0.32-2.30
MMP2 n = 668       
C/C 481 446 10.0 1.00   1.00  
C/T 174 164 9.4 1.10 0.92-1.32 1.12 0.93-1.35
T/T 13 12 10.6 1.37 0.77-2.44 1.79 1.00-3.20
MMP3 n = 593       
6A/6A 148 137 14.1 1.00   1.00  
6A/5A 300 282 9.1 1.16 0.95-1.43 0.95 0.77-1.18
5A/5A 145 135 9.3 1.09 0.86-1.39 0.92 0.72-1.18
  1. aAdjusted by age, gender, pack-years, histological type, clinical stage, surgical operation and radio and chemotherapy
  2. MST: median survival time